Changes in electrical activity of heart during ischemic–reperfusion injury modified by the administration of antidepressants

[1] Abozguia K, Chudley S., Gammage M. Dose-dependent venlafaxine-induced sinus tachycardia. Int J Cardiol. 2006;113:E9-E1010.1016/j.ijcard.2006.01.07216989912Search in Google Scholar

[2] Hanash JA, Hansen BH, Hansen JF, Nielsen OW, Rasmussen A, Birket-Smith M. Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the Depression in patients with Coronary Artery Disease (DECARD) trial. J Cardiovasc Pharmacol. 2012;60(4): 397-405.10.1097/FJC.0b013e318267704122820898Search in Google Scholar

[3] Leonard C.E., Bilker W.B., Newcomb C., Kimmel S.E., Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol. Drug Saf. 2011;20: 903-913. Search in Google Scholar

[4] Ma-Li, Wong D.CH., Esporito K., Thakur S., Liu W., Elashoff R.M., Licinio J. Elevated Stress-Hemoconcentration in Major Depression is Normalized by Antidepressant Treatment: Secondary Analysis for a Randomized, Double-Blind Clinical Trial and Relevance to Cardiovascular Disease Risk. PLOS ONE. 2008;7: 1-6.Search in Google Scholar

[5] Nezafati M, Vojdanparast M, Nezafati P. Antidepressants and cardiovascular adverse events: A narrative review. ARYA Atherosclerosis. 2015;11(5):295-304.Search in Google Scholar

[6] Noordam R, Van den Berg M, Visser L, et al. Assessing Prolongation of the Heart Rate Corrected QT Interval in Users of Tricyclic Antidepressants: Advice to Use Fridericia Rather Than Bazett’s Correction. Journal Of Clinical Psychopharmacology. 2015;35(3):260-265.10.1097/JCP.000000000000032125856783Search in Google Scholar

[7] Pacher P. and Valeria K. Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, Old Concerns? Curr. Pharmac. Des. 2004;10.20: 2463-2475.10.2174/1381612043383872249329515320756Search in Google Scholar

[8] Sicouri S. and Charles A. Sudden Cardiac Death Secondary to Antidepressant and Antipsychotic Drugs. Expert opinion on drug safety 2008;181-194.10.1517/14740338.7.2.181236573118324881Search in Google Scholar

[9] Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol 2013;23(11): 1391-400.10.1016/j.euroneuro.2013.05.01123928296Search in Google Scholar

[10] Unterecker S, Pfuhlmann B, Kopf J, Kittel-Schneider S, Reif A, Deckert J. Increase of Heart Rate and QTc by Amitriptyline, But Not by Venlafaxine, Is Correlated to Serum Concentration. Journal Of Clinical Psychopharmacology. 2015;35(4):460-46310.1097/JCP.000000000000033626035054Search in Google Scholar

[11] Vicen M, Gulač P, Stankovičova T, et al., . Efekt jednodňovej premedikacie antidepresivami na funkciu srdca potkanov. Farmaceuticky obzor, 2015, 1-2, 21-25 (in slovak)Search in Google Scholar

[12] Wang J, Ke D, Lin M. Heat shock pretreatment may protect against heatstroke-induced circulatory shock and cerebral ischemia by reducing oxidative stress and energy depletion. Shock. February 2005;23(2):161-167.Search in Google Scholar

[13] Waring W.S. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Health cPatient Saf. 2012;4: 93-101.Search in Google Scholar

[14] WHO, The top 10 causes of death (http://www.who.int/mediacentre/factsheets/fs310/en/) Revised May 2014 Accessed December 20, 2015 Search in Google Scholar